191 related articles for article (PubMed ID: 38280072)
21. [Monitoring of early Epstein-Barr virus reactivation and preemptive therapy after allogeneic hematopoietic stem cell transplantation].
Lu Y; Wu T; Cao XY; Wang JB; Sun Y; Zhao YL; DA WM; Ji SQ; Tong CR; Lu DP
Zhonghua Nei Ke Za Zhi; 2011 May; 50(5):383-7. PubMed ID: 21624219
[TBL] [Abstract][Full Text] [Related]
22. Both high and low levels of cellular Epstein-Barr virus DNA in blood identify failure after hematologic stem cell transplantation in conjunction with acute GVHD and type of conditioning.
Li Q; Rane L; Poiret T; Zou J; Magalhaes I; Ahmed R; Du Z; Vudattu N; Meng Q; Gustafsson-Jernberg Å; Winiarski J; Ringdén O; Maeurer M; Remberger M; Ernberg I
Oncotarget; 2016 May; 7(21):30230-40. PubMed ID: 27102298
[TBL] [Abstract][Full Text] [Related]
23. Reconstitution of Human Cytomegalovirus-Specific CD4+ T Cells is Critical for Control of Virus Reactivation in Hematopoietic Stem Cell Transplant Recipients but Does Not Prevent Organ Infection.
Gabanti E; Lilleri D; Ripamonti F; Bruno F; Zelini P; Furione M; Colombo AA; Alessandrino EP; Gerna G
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2192-2202. PubMed ID: 26260678
[TBL] [Abstract][Full Text] [Related]
24. Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trial.
Xu X; Fan Z; Wang Y; Huang F; Xu Y; Sun J; Xu N; Deng L; Li X; Liang X; Luo X; Shi P; Liu H; Chen Y; Tu S; Huang X; Liu Q; Xuan L
BMC Med; 2022 Sep; 20(1):282. PubMed ID: 36050712
[TBL] [Abstract][Full Text] [Related]
25. Optimal Active Anti-Thymocyte Globulin Exposure Associated with Minimum Risk of Virus Reactivation and Comparable Acute Graft-Versus-Host Disease Under Adult Myeloablative Haploidentical Peripheral Blood Stem Cell Transplantation.
Wang H; Zhao Y; Fang S; Wang L; Peng B; Yang J; Wang N; Du J; Li F; Jin X; Luan S; Wu X; Dou L; Liu D
Transplant Cell Ther; 2022 Jun; 28(6):332.e1-332.e10. PubMed ID: 35314377
[TBL] [Abstract][Full Text] [Related]
26. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT.
van Esser JW; van der Holt B; Meijer E; Niesters HG; Trenschel R; Thijsen SF; van Loon AM; Frassoni F; Bacigalupo A; Schaefer UW; Osterhaus AD; Gratama JW; Löwenberg B; Verdonck LF; Cornelissen JJ
Blood; 2001 Aug; 98(4):972-8. PubMed ID: 11493441
[TBL] [Abstract][Full Text] [Related]
27. Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation.
Massoud R; Gagelmann N; Fritzsche-Friedland U; Zeck G; Heidenreich S; Wolschke C; Ayuk F; Christopeit M; Kröger N
Haematologica; 2022 Apr; 107(4):857-867. PubMed ID: 33832208
[TBL] [Abstract][Full Text] [Related]
28. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.
Ma CK; Blyth E; Clancy L; Simms R; Burgess J; Brown R; Deo S; Micklethwaite KP; Gottlieb DJ
Cytotherapy; 2015 Oct; 17(10):1406-20. PubMed ID: 26349000
[TBL] [Abstract][Full Text] [Related]
29. Virus reactivation and low dose of CD34+ cell, rather than haploidentical transplantation, were associated with secondary poor graft function within the first 100 days after allogeneic stem cell transplantation.
Sun YQ; Wang Y; Zhang XH; Xu LP; Liu KY; Yan CH; Liu ZY; Huang XJ
Ann Hematol; 2019 Aug; 98(8):1877-1883. PubMed ID: 31144019
[TBL] [Abstract][Full Text] [Related]
30. CMV infection combined with acute GVHD associated with poor CD8+ T-cell immune reconstitution and poor prognosis post-HLA-matched allo-HSCT.
Fan ZY; Han TT; Zuo W; Zhao XS; Chang YJ; Lv M; Mo XD; Sun YQ; Zhang YY; Wang Y; Xu LP; Zhang XH; Liu KY; Huang XJ; Zhao XY
Clin Exp Immunol; 2022 Jun; 208(3):332-339. PubMed ID: 35551362
[TBL] [Abstract][Full Text] [Related]
31. Risk Factors for and the Clinical Impact of Cytomegalovirus and Epstein-Barr Virus Infections in Pediatric Recipients of TCR-α/β- and CD19-Depleted Grafts.
Laberko A; Bogoyavlenskaya A; Shelikhova L; Shekhovtsova Z; Balashov D; Voronin K; Kurnikova E; Boyakova E; Raykina E; Brilliantova V; Pirumova V; Novichkova G; Maschan A; Maschan M
Biol Blood Marrow Transplant; 2017 Mar; 23(3):483-490. PubMed ID: 28039080
[TBL] [Abstract][Full Text] [Related]
32. Immune recovery and the risk of CMV/ EBV reactivation in children post allogeneic haematopoietic stem cell transplantation.
Janeczko M; Mielcarek M; Rybka B; Ryczan-Krawczyk R; Noworolska-Sauren D; Kałwak K
Cent Eur J Immunol; 2016; 41(3):287-296. PubMed ID: 27833447
[TBL] [Abstract][Full Text] [Related]
33. Cytomegalovirus reactivation is associated with an increased risk of late-onset invasive aspergillosis independently of grade II-IV acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: JSTCT Transplant Complications Working Group.
Kimura SI; Tamaki M; Okinaka K; Seo S; Uchida N; Igarashi A; Ozawa Y; Ikegame K; Eto T; Tanaka M; Shiratori S; Nakamae H; Sawa M; Kawakita T; Onizuka M; Fukuda T; Atsuta Y; Kanda Y; Nakasone H
Ann Hematol; 2021 Dec; 100(12):3029-3038. PubMed ID: 34490500
[TBL] [Abstract][Full Text] [Related]
34. Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: a pilot prospective study.
Liu X; Wu M; Peng Y; Chen X; Sun J; Huang F; Fan Z; Zhou H; Wu X; Yu G; Zhang X; Li Y; Xiao Y; Song C; Xiang AP; Liu Q
Cell Transplant; 2014; 23(9):1087-98. PubMed ID: 23294601
[TBL] [Abstract][Full Text] [Related]
35. Immune reconstitution of HLA-A*0201/BMLF1- and HLA-A*1101/LMP2-specific Epstein Barr virus cytotoxic T lymphocytes within 90 days after haploidentical hematopoietic stem cell transplantation.
Zhou L; Lu DP
Virol J; 2019 Feb; 16(1):19. PubMed ID: 30736814
[TBL] [Abstract][Full Text] [Related]
36. [Value of CD3
Mo WJ; Sun QQ; Pan SY; Mao P; Chen XW; Zhang YP; Zhou M; Xiu YL; Wang SQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1761-1767. PubMed ID: 29262912
[TBL] [Abstract][Full Text] [Related]
37. Inverse correlation of Vδ2
Liu J; Bian Z; Wang X; Xu LP; Fu Q; Wang C; Chang YJ; Wang Y; Zhang XH; Jiang Z; Huang XJ
Br J Haematol; 2018 Jan; 180(2):276-285. PubMed ID: 29270985
[TBL] [Abstract][Full Text] [Related]
38. Real world experience: Examining outcomes using letermovir for CMV prophylaxis in high-risk allogeneic hematopoietic stem cell patients in the setting of using T-cell depletion as GVHD prophylaxis.
Dwabe S; Hsiao M; Ali A; Rodman J; Savitala-Damerla L; Nazaretyan S; Kimberly Schiff NP; Tam E; Ladha A; Woan K; Chaudhary P; Yaghmour G
Transpl Immunol; 2023 Feb; 76():101769. PubMed ID: 36464218
[TBL] [Abstract][Full Text] [Related]
39. HHV-6 infection after allogeneic hematopoietic stem cell transplantation: From chromosomal integration to viral co-infections and T-cell reconstitution patterns.
Quintela A; Escuret V; Roux S; Bonnafous P; Gilis L; Barraco F; Labussière-Wallet H; Duscastelle-Leprêtre S; Nicolini FE; Thomas X; Chidiac C; Ferry T; Frobert E; Morisset S; Poitevin-Later F; Monneret G; Michallet M; Ader F;
J Infect; 2016 Feb; 72(2):214-22. PubMed ID: 26518057
[TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr Virus Reactivation After Paediatric Haematopoietic Stem Cell Transplantation: Risk Factors and Sensitivity Analysis of Mathematical Model.
Kania SP; Silva JMF; Charles OJ; Booth J; Cheung SYA; Yates JWT; Worth A; Breuer J; Klein N; Amrolia PJ; Veys P; Standing JF
Front Immunol; 2022; 13():903063. PubMed ID: 35903096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]